YUMAB develops fully human antibodies from target to lead for clients and partners worldwide.
Its proprietary antibody platform covers all technologies from antibody discovery – using one of the world’s largest, natural human antibody library collection (>10e11) or customized, patient-derived or immune libraries – to antibody engineering and lead optimization.
YUMAB antibodies contain natural, close to germ-line sequences promising low immunogenicity and toxicity. The advanced in vitro and on-cell selection technologies pre-design antibody properties, such as interspecies X-reactivity and developability, early in the development process and provide high success-rates to all types of antigens, including difficult targets like GPCRs or ion channels. Bioinformatic optimization and in vitro evolution technologies provide a direct path towards optimized lead candidates for all antibody drug formats such as full-length IgG, Fab, scFv, bispecifics, CARs, fusion proteins and ADCs.